Ignite Creation Date:
2025-12-24 @ 7:30 PM
Ignite Modification Date:
2026-01-04 @ 1:48 PM
Study NCT ID:
NCT04820803
Status:
COMPLETED
Last Update Posted:
2021-07-07
First Post:
2021-03-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D008722', 'term': 'Methods'}, {'id': 'D002594', 'term': 'Cetylpyridinium'}], 'ancestors': [{'id': 'D008919', 'term': 'Investigative Techniques'}, {'id': 'D011726', 'term': 'Pyridinium Compounds'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR'], 'maskingDescription': 'Randomized double-blind pilot clinical trial (evaluator and patients) in patients with a diagnosis of COVID-19 and symptoms of the disease.'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a bilateral contrast, 40 subjects in the first group and 40 in the second were required to detect a difference equal to or greater than 5 units. The common standard deviation is assumed to be 10 (12). A loss to follow-up rate of 20% has been estimated.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 80}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-02-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-03', 'completionDateStruct': {'date': '2021-06-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-07-01', 'studyFirstSubmitDate': '2021-03-23', 'studyFirstSubmitQcDate': '2021-03-26', 'lastUpdatePostDateStruct': {'date': '2021-07-07', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-03-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-04-29', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Threshold cycle value of SARS-CoV-2 by Polymerase Chain Reaction (PCR) in saliva samples', 'timeFrame': '3 months', 'description': 'Threshold cycle value of SARS-CoV-2 by Polymerase Chain Reaction (PCR) in saliva samples before antd 2hours after mouthwashes'}, {'measure': 'SARS-CoV-2 Nucleocapsid protein in saliva by ELISA', 'timeFrame': '3 months', 'description': 'Quantitative determination of SARS-CoV-2 Nucleocapsid protein in saliva by ELISA'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['cetylpyridinium', 'SARS-CoV-2', 'COVID-19', 'mouthwashes'], 'conditions': ['COVID-19', 'SARS-CoV-2 Infection']}, 'descriptionModule': {'briefSummary': 'Pilot, randomized and controlled clinical trial for the evaluation of the decrease in the viral load of SARS-CoV-2 in the oropharynx in patients with COVID-19 through the use of mouthwash containing cetylpyridinium chloride (CPC) (0.07%) in mouthwash.', 'detailedDescription': 'The objective of the clinical trial is to determine the short-term efficacy of cetylpyridinium chloride (CPC) mouthwashes to assess changes in the threshold cycle value of the analysis of the SARS-CoV-2 oropharyngeal saliva sample, in patients diagnosed with COVID-19 and with symptomatology compatible with the disease. A randomized double-blind pilot clinical trial (evaluator and patients) will be developed in patients with a diagnosis of COVID-19 and symptoms of the disease. The experimental group will perform a single rinse with a mouthwash containing Cetylpyridinium Chloride (CPC) while the placebo group will perform the same rinse, but with a harmless liquid that will act as a placebo. The study will be carried out in the Zaragoza III Health Sector, with patients belonging to the Zaragoza II Health Sector, collaborating with the "Seminario" health center and the Lozano Blesa Clinical University Hospital (HCULB). This project will be carried out in accordance with the CONSORT guidelines for clinical trials.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Outpatients older than 18 years and younger than 80 years.\n* Patients with a medical indication for a diagnostic test for active infection to SARS-CoV-2\n* Patients who present mild symptoms typical of COVID-19 and who have less than three days of evolution\n* Patients who have cognitive and motor skills to perform mouthwash correctly.\n* Patients who understand and speak Spanish\n* Patients who freely give their consent to participate in the study, after a correct understanding of its objectives and procedures.\n\nExclusion Criteria:\n\n* Patients with hospitalization criteria (moderate or severe symptoms)\n* Vulnerable populations such as pregnant, lactating,\n* Patients with recent medical diagnosis (≤ 1 month) of pneumonia\n* Patients with hyposialia\n* Patients with consumption of oral antiseptics (in the form of mouthwash containing CPC, povidone iodine rinses, alcohol mouthwash and essential oils) and toothpastes with CPC during the last month.\n* Patients with cognitive impairment'}, 'identificationModule': {'nctId': 'NCT04820803', 'briefTitle': 'Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19', 'organization': {'class': 'OTHER', 'fullName': 'Instituto de Investigación Sanitaria Aragón'}, 'officialTitle': 'PILOT CLINICAL TRIAL TO ASSESS THE IMPACT OF ORAL INTERVENTION WITH CETIL PYRIDINIUM CHLORIDE TO REDUCE THE VIRAL LOAD OF SARS-CoV-2', 'orgStudyIdInfo': {'id': 'CPC01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cetylpyridinium Chloride (CPC) 0,07%', 'description': 'patients who rinse with cetylpyiridinium chloride 0,07% mouthwash for 60 seconds', 'interventionNames': ['Other: ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo: Distilled water with the same flavor and coloring as the product to be evaluated', 'description': 'patients who rinse with distilled water mouthwash for 60 seconds', 'interventionNames': ['Other: PLACEBO']}], 'interventions': [{'name': 'ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE', 'type': 'OTHER', 'description': 'one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds', 'armGroupLabels': ['Cetylpyridinium Chloride (CPC) 0,07%']}, {'name': 'PLACEBO', 'type': 'OTHER', 'description': 'one mouthwash containing distilled (placebo) water for 60 seconds', 'armGroupLabels': ['Placebo: Distilled water with the same flavor and coloring as the product to be evaluated']}]}, 'contactsLocationsModule': {'locations': [{'zip': '50009', 'city': 'Zaragoza', 'country': 'Spain', 'facility': 'Seminario Health Center and Lozano Blesa University Clinical Hospital', 'geoPoint': {'lat': 41.65606, 'lon': -0.87734}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Rosa Tarrago', 'class': 'OTHER'}, 'collaborators': [{'name': 'Dentaid SL', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Principal investigator', 'investigatorFullName': 'Rosa Tarrago', 'investigatorAffiliation': 'Instituto de Investigación Sanitaria Aragón'}}}}